Chronic Graft-versus-host-disease Clinical Trial
Official title:
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Verified date | December 2023 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy
Status | Terminated |
Enrollment | 159 |
Est. completion date | December 11, 2023 |
Est. primary completion date | December 11, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: 1. Male and female subjects at least 12 years of age who have had allogenic hematopoietic cell transplant (HCT). 2. Previously received at least 2 and not more than 5 lines of systemic therapy for cGVHD 3. Receiving glucocorticoid therapy with a stable dose over the 2 weeks prior to screening 4. Have persistent cGVHD manifestations and systemic therapy is indicated 5. Karnofsky Performance Score of = 60 (if aged 16 years or older); Lansky Performance Score of = 60 (if aged < 16 years) 6. Weight = 40kg Exclusion Criteria: 1. Subjects has not been on a stable dose / regimen of systemic cGVHD treatments for at least 2 weeks prior to screening. (Note: Concomitant corticosteroids, calcineurin inhibitors, sirolimus, MMF, methotrexate, rituximab, and extracorporeal photophoresis (ECP) are acceptable. Systemic investigational GVHD treatments are not permitted). 2. Histological relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening. 3. Current treatment with ibrutinib. Prior treatment with ibrutinib is allowed with a washout of at least 28 days prior to randomization. |
Country | Name | City | State |
---|---|---|---|
United States | CS Mott Children's Hospital Site Number : 157 | Ann Arbor | Michigan |
United States | Emory University School of Medicine Site Number : 100 | Atlanta | Georgia |
United States | Augusta University Medical Center Site Number : 093 | Augusta | Georgia |
United States | South Austin Medical Center Site Number : 091 | Austin | Texas |
United States | Center for Cancer Research National Cancer Institute Site Number : 107 | Bethesda | Maryland |
United States | University of Alabama at Birmingham (UAB) - Children's of Alabama Site Number : 156 | Birmingham | Alabama |
United States | Dana-Farber Cancer Institute Site Number : 004 | Boston | Massachusetts |
United States | Massachusetts General Hospital Site Number : 002 | Boston | Massachusetts |
United States | University of Illinois at Chicago Site Number : 139 | Chicago | Illinois |
United States | The Cleveland Clinic Foundation Site Number : 041 | Cleveland | Ohio |
United States | James Cancer Hospital & Wexner Medical Center at the Ohio State University Comprehensive Cancer Center Site Number : 103 | Columbus | Ohio |
United States | University of Texas Southwestern Site Number : 155 | Dallas | Texas |
United States | Colorado Blood Cancer Institute Site Number : 098 | Denver | Colorado |
United States | Barbara Ann Karmanos Cancer Institute-4100 John R St Site Number : 094 | Detroit | Michigan |
United States | Childrens Hospital of Michigan Site Number : 161 | Detroit | Michigan |
United States | City of Hope Medical Center Site Number : 050 | Duarte | California |
United States | University of Kansas Cancer Center Site Number : 105 | Fairway | Kansas |
United States | MD Anderson Cancer Center Site Number : 057 | Houston | Texas |
United States | University of Iowa Site Number : 126 | Iowa City | Iowa |
United States | University of California, Los Angeles (UCLA) - Medical Center Site Number : 104 | Los Angeles | California |
United States | University of Wisconsin - Carbone Cancer Center Site Number : 135 | Madison | Wisconsin |
United States | University of Miami - Sylvester Cancer Center Site Number : 097 | Miami | Florida |
United States | Froedtert Hospital and the Medical College of Wisconsin Site Number : 101 | Milwaukee | Wisconsin |
United States | University of Minnesota Site Number : 051 | Minneapolis | Minnesota |
United States | Sarah Cannon and HCA Research Institute Site Number : 007 | Nashville | Tennessee |
United States | Vanderbilt University Medical Center Site Number : 063 | Nashville | Tennessee |
United States | Childrens Hospital of Orange County Site Number : 165 | Orange | California |
United States | Phoenix Childrens Hospital Site Number : 154 | Phoenix | Arizona |
United States | University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Site Number : 132 | Pittsburgh | Pennsylvania |
United States | Oregon Health & Science University (OHSU) Site Number : 095 | Portland | Oregon |
United States | University of Rochester Site Number : 106 | Rochester | New York |
United States | Washington University School of Medicine Site Number : 125 | Saint Louis | Missouri |
United States | Texas Transplant Institute Site Number : 079 | San Antonio | Texas |
United States | University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center Site Number : 058 | San Francisco | California |
United States | Fred Hutchinson Cancer Research Center Site Number : 052 | Seattle | Washington |
United States | Stanford Cancer Center Site Number : 108 | Stanford | California |
United States | Moffitt Site Number : 102 | Tampa | Florida |
United States | University of Arizona - Cancer Center Site Number : 122 | Tucson | Arizona |
United States | Wake Forest Site Number : 123 | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Kadmon, a Sanofi Company |
United States,
Przepiorka D, Le RQ, Ionan A, Li RJ, Wang YH, Gudi R, Mitra S, Vallejo J, Okusanya OO, Ma L, Yang Y, Patel P, Mezaache D, Shah R, Banerjee A, McLamore S, Maung AN, Goldberg KB, Pazdur R, Theoret MR, De Claro RA. FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy. Clin Cancer Res. 2022 Jun 13;28(12):2488-2492. doi: 10.1158/1078-0432.CCR-21-4176. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Response Rate (ORR) | The primary endpoint is the ORR with responses as defined by the 2014 National Institute of Health (NIH) Consensus Development Project on clinical trials in cGVHD. | up to approximately 40 months | |
Secondary | Duration of Response (DOR) | The time from initial response of PR or CR until documented progression of cGVHD | up to approximately 40 months | |
Secondary | Change in Lee Symptom Scale Score | Analyses will include: Number of subjects with a =7 point reduction, Number of subjects with a =7 point reduction on 2 consecutive assessments and Duration of a =7 point reduction. Symptom burden will be assessed on Day 1 of each cycle starting on Cycle 1 Day 1, as well as at the EOT visit. The questionnaire asks subjects to indicate the degree of bother that they experienced due to symptoms in seven domains potentially affected by chronic GVHD (skin, eyes, mouth, breathing, eating and digestion, energy, and emotional distress). The response will be determined based on clinician assessment specifically for each of affected organ as a Complete Response, Partial Response or Progression. | up to approximately 40 months | |
Secondary | Response rate by organ system | The response assessment for the nine individual organs (Skin, Eyes, Mouth, Esophagus, Upper GI, Lower GI, Liver, Lungs, and Joints and fascia). | up to approximately 40 months | |
Secondary | Percentage of subjects who have a best response of PR or CR | up to approximately 40 months | ||
Secondary | Change in corticosteroid dose | up to approximately 40 months | ||
Secondary | Change in calcineurin inhibitor dose | up to approximately 40 months | ||
Secondary | Failure-free survival (FFS) | FFS is defined as the absence of cGVHD treatment change, non-relapse mortality and recurrent malignancy. Median FFS (from first dose of belumosudil) and landmark FFS at 1 year will be analyzed. | up to approximately 7 years | |
Secondary | Overall Survival (OS) | Time from first dose of belumosudil to the date of death due to any cause. | up to approximately 7 years | |
Secondary | Change in cGVHD severity as based on the Physician-reported global cGVHD Activity Assessment | Physician-reported outcome | up to approximately 40 months | |
Secondary | Change in symptom activity as based on cGVHD Activity Assessment Patient Self-Report | Patient-reported outcome | up to approximately 40 months | |
Secondary | Determine the Peak Plasma Concentration (Cmax) of belumosudil | Determine the maximum plasma concentration (Cmax) of belumosudil | Pre-dose and post-dose sampling within 12 hours | |
Secondary | Determine the observed time to reach peak plasma concentration (Tmax) of belumosudil | The time that belumosudil reach the maximum plasma concentration (Tmax). | Pre-dose and post-dose sampling within 12 hours | |
Secondary | Determine the half-life (T1/2) of belumosudil | The time it takes for half of belumosudil to be removed from plasma by biological processes (T1/2) | Pre-dose and post-dose sampling within 12 hours | |
Secondary | Determine the area under the plasma concentration versus time curve (AUC) of belumosudil | Area under the plasma concentration versus time curve (AUC) | Pre-dose and post-dose sampling within 12 hours | |
Secondary | Time to Response | The time it takes to obtain a cGVHD response to belumosudil. | up to approximately 40 months | |
Secondary | Time to next treatment | The time it takes to initiate a new systemic cGVHD treatment after starting belumosudil. | up to approximately 40 months | |
Secondary | Number pf participants with adverse event and serious adverse events | Safety will be assessed by monitoring adverse events, clinical laboratory evaluations, vital sign measurements, and ECG parameters. | Up to 28 days after the last dose of study treatment i.e., up to approximately 7 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04189432 -
Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease
|
Phase 2 | |
Terminated |
NCT03557749 -
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
|
||
Completed |
NCT05121142 -
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
|
Phase 1 | |
Recruiting |
NCT04202835 -
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
|
Phase 2 | |
Completed |
NCT01036958 -
Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease
|
||
Recruiting |
NCT04372524 -
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
|
||
Active, not recruiting |
NCT03604692 -
A Phase 1/2 Study to Evaluate SNDX- 6352 in Participants With Active cGVHD
|
Phase 1/Phase 2 | |
Recruiting |
NCT05355675 -
The Association of Microbiota Composition With cGVHD After Allo-HSCT
|
||
Active, not recruiting |
NCT04710576 -
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
|
Phase 2 | |
Terminated |
NCT04200365 -
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
|
Phase 2 | |
Not yet recruiting |
NCT06263478 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
|
Phase 3 | |
Not yet recruiting |
NCT06388564 -
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
|
Phase 2 | |
Terminated |
NCT02123966 -
An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease
|
Phase 2 | |
Recruiting |
NCT05692713 -
Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
|
||
Terminated |
NCT04446182 -
Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD
|
Phase 2 | |
Active, not recruiting |
NCT05305989 -
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
|
Phase 2 | |
Active, not recruiting |
NCT02340676 -
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
|
Phase 2 | |
Completed |
NCT04540133 -
Dexamethasone Solution and Dexamethasone in Mucolox™
|
Phase 2 | |
Not yet recruiting |
NCT03190733 -
A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT
|
Phase 4 | |
Active, not recruiting |
NCT04716075 -
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
|
Phase 2 |